Search

Your search keyword '"Farkas, Klaudia"' showing total 661 results
Start Over Author "Farkas, Klaudia"
661 results on '"Farkas, Klaudia"'

101. Histological activity and basal plasmacytosis are nonpredictive markers for subsequent relapse in ulcerative colitis patients with mucosal healing

Author

Tiszlavicz László, Szucs Monika, Rutka Mariann, Reisz Zita, Molnár Tamás, Bálint Anita, Sejben Anita, Farkas Klaudia, Nagy Ferenc, Szepes Zoltán, Milassin Ágnes, Nyari Tibor, and Bor Renáta

Subjects
Pathology, medicine.medical_specialty, Basal (phylogenetics), Subsequent Relapse, business.industry, Mucosal healing, Plasmacytosis, medicine, medicine.disease, business, Ulcerative colitis
Published
2016
Full Text
View/download PDF

102. Real-life efficacy of vedolizumab on endoscopic healing in inflammatory bowel disease – A nationwide Hungarian cohort study

Author

Bor, Renáta, primary, Fábián, Anna, additional, Matuz, Mária, additional, Szepes, Zoltán, additional, Farkas, Klaudia, additional, Miheller, Pál, additional, Szamosi, Tamás, additional, Vincze, Áron, additional, Rutka, Mariann, additional, Szántó, Kata, additional, Bálint, Anita, additional, Nagy, Ferenc, additional, Milassin, Ágnes, additional, Tóth, Tibor, additional, Zsigmond, Ferenc, additional, Bajor, Judit, additional, Müllner, Katalin, additional, Lakner, Lilla, additional, Papp, Mária, additional, Salamon, Ágnes, additional, Horváth, Gábor, additional, Sarang, Krisztina, additional, Schäfer, Eszter, additional, Sarlós, Patrícia, additional, Palatka, Károly, additional, and Molnár, Tamás, additional

Published
2019
Full Text
View/download PDF

104. Mo1892 – Non-Medical Reverse Switch Between the Originator Infliximab and Its Biosimilar in Patients with Inflammatory Bowel Disease: Clinical Outcomes and Therapeutic Drug Monitoring

Author

Gonczi, Lorant, primary, Ilias, Akos, additional, Szanto, Kata, additional, Kurti, Zsuzsanna, additional, Golovics, Petra Anna, additional, Farkas, Klaudia, additional, Schafer, Eszter, additional, Szepes, Zoltán, additional, Szalay, Balazs, additional, Vincze, Aron, additional, Szamosi, Tamas, additional, Molnar, Tamas, additional, and Lakatos, Peter L., additional

Published
2019
Full Text
View/download PDF

107. Polyunsaturated fatty acids synergize with lipid droplet binding thalidomide analogs to induce oxidative stress in cancer cells

Author

Madácsi Ramóna, Kanizsai Iván, Gyuris Márió, Magyary István, Molnár Eszter, Rásó Erzsébet, Ayaydin Ferhan, Vizler Csaba, Fehér Liliána Z, Puskás László G, Fábián Gabriella, Farkas Klaudia, Hegyi Péter, Baska Ferenc, Ózsvári Béla, and Kitajka Klára

Subjects
Nutritional diseases. Deficiency diseases, RC620-627
Abstract

Abstract Background Cytoplasmic lipid-droplets are common inclusions of eukaryotic cells. Lipid-droplet binding thalidomide analogs (2,6-dialkylphenyl-4/5-amino-substituted-5,6,7-trifluorophthalimides) with potent anticancer activities were synthesized. Results Cytotoxicity was detected in different cell lines including melanoma, leukemia, hepatocellular carcinoma, glioblastoma at micromolar concentrations. The synthesized analogs are non-toxic to adult animals up to 1 g/kg but are teratogenic to zebrafish embryos at micromolar concentrations with defects in the developing muscle. Treatment of tumor cells resulted in calcium release from the endoplasmic reticulum (ER), induction of reactive oxygen species (ROS), ER stress and cell death. Antioxidants could partially, while an intracellular calcium chelator almost completely diminish ROS production. Exogenous docosahexaenoic acid or eicosapentaenoic acid induced calcium release and ROS generation, and synergized with the analogs in vitro, while oleic acid had no such an effect. Gene expression analysis confirmed the induction of ER stress-mediated apoptosis pathway components, such as GADD153, ATF3, Luman/CREB3 and the ER-associated degradation-related HERPUD1 genes. Tumor suppressors, P53, LATS2 and ING3 were also up-regulated in various cell lines after drug treatment. Amino-phthalimides down-regulated the expression of CCL2, which is implicated in tumor metastasis and angiogenesis. Conclusions Because of the anticancer, anti-angiogenic action and the wide range of applicability of the immunomodulatory drugs, including thalidomide analogs, lipid droplet-binding members of this family could represent a new class of agents by affecting ER-membrane integrity and perturbations of ER homeostasis.

Published
2010
Full Text
View/download PDF

111. Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune‐mediated inflammatory diseases: A European retrospective observational study

Author

Goessens, Laurent, Colombel, Jean‐Frédéric, Outtier, An, Ferrante, Marc, Sabino, Joao, Judge, Ciaran, Saeidi, Reza, Rabbitt, Louise, Armuzzi, Alessandro, Domenech, Eugeni, Michalopoulos, George, Cremer, Anneline, García‐Alonso, Francisco Javier, Molnar, Tamas, Karmiris, Konstantinos, Gecse, Krisztina, Van Oostrom, Joep, Löwenberg, Mark, Farkas, Klaudia, Atreya, Raja, Ribaldone, Davide Giuseppe, Selinger, Christian, Hoentjen, Frank, Bihin, Benoit, Sebastian, Shaji, and Rahier, Jean‐François

Abstract

Few data are available regarding the combination of biologics or small molecules in inflammatory bowel disease (IBD) patients. We report safety and efficacy of such combinations through a retrospective multicentre series. Combination therapy was defined as the concomitant use of two biologics or one biologic with a small molecule. Patient demographics, disease characteristics and types of combinations were recorded. Safety was evaluated according to the occurrence of serious infection, opportunistic infection, hospitalisation, life‐threatening event, worsening of IBD or immune‐mediated inflammatory diseases (IMID), cancer and death. Efficacy was evaluated as the physician global assessment of the combination and comparison of clinical/endoscopic scores of IBD/IMID activity prior and during combination. A total of 104 combinations were collected in 98 patients. Concomitant IMID were present in 41 patients. Reasons for starting combination therapy were active IBD (67%), active IMID or extra‐intestinal manifestations (EIM) (22%), both (10%) and unclassified in 1. Median duration of combination was 8 months (interquartile range 5–16). During 122 patient‐years of follow‐up, 42 significant adverse events were observed, mostly related to uncontrolled IBD. There were 10 significant infections, 1 skin cancer and no death. IBD disease activity was clinically improved in 70% and IMID/EIM activity in 81% of the patients. Overall, combination was continued in 55% of the patients. Combination of biologics and small molecules in patients with IBD and IMID/EIM seems to be a promising therapeutic strategy but is also associated with a risk of opportunistic infections or infections leading to hospitalisation in 10%.

Published
2021
Full Text
View/download PDF

112. Product Developments and Dissemination Activities

Author

Amado, Miguel Pires, primary, Farkas, Klaudia, additional, Frontini, Francesco, additional, Giovanardi, Alessia, additional, Gosztonyi, Susanne, additional, Hachem, Caroline, additional, Hoff, Merete, additional, Korolkow, Margarethe, additional, Lundgren, Marja, additional, Maturi, Laura, additional, Cristina, Maria, additional, Probst, Munari, additional, Roecker, Christian, additional, Scognamiglio, Alessandra, additional, and Snow, Mark, additional

Published
2012
Full Text
View/download PDF

113. Effect of COVID-19 pandemic on workflows and infection prevention strategies of endoscopy units in Hungary: a cross-sectional survey.

Author

Bor, Renáta, Szántó, Kata Judit, Fábián, Anna, Farkas, Klaudia, Szűcs, Mónika, Rutka, Mariann, Tóth, Tibor, Bálint, Anita, Milassin, Ágnes, Dubravcsik, Zsolt, Szepes, Zoltán, Molnár, Tamás, and Hungarian GI Endoscopy COVID-19 Study Group

Subjects
COVID-19 pandemic, INFECTION prevention, MEDICAL personnel, FOREIGN bodies, ENDOSCOPY, SURGICAL gloves, COVID-19
Abstract

Background: Health care professionals in endoscopic labs have an elevated risk for COVID-19 infection, therefore, we aimed to determine the effect of current pandemic on the workflow and infection prevention and control strategies of endoscopy units in real-life setting.Methods: All members of Hungarian Society of Gastroenterology were invited between 7 and 17 April 2020 to participate in this cross-section survey study and to complete an online, anonymous questionnaire.Results: Total of 120 endoscopists from 83 institutes were enrolled of which 35.83% worked in regions with high cumulative incidence of COVID-19. Only 33.33% of them had undergone training about infection prevention in their workplace. 95.83% of endoscopists regularly used risk stratification of patients for infection prior endoscopy. While indications of examinations in low risk patients varied widely, in high-risk or positive patients endoscopy was limited to gastrointestinal bleeding (95.00%), removal of foreign body from esophagus (87.50%), management of obstructive jaundice (72.50%) and biliary pancreatitis (67.50%). Appropriate amount of personal protective equipment was available in 60.85% of endoscopy units. In high-risk or positive patients, surgical mask, filtering facepiece mask, protective eyewear and two pairs of gloves were applied in 30.83%, 76.67%, 90.00% and 87.50% of cases, respectively. Personal protective equipment fully complied with European guideline only in 67.50% of cases.Conclusions: Survey found large variability in indications of endoscopy and relative weak compliance to national and international practical recommendations in terms of protective equipment. This could be improved by adequate training about infection prevention. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

114. Endoscopic treatment of gastric antral vascular ectasia in real‐life settings: Argon plasma coagulation or endoscopic band ligation?

Author

Fábián, Anna, Bor, Renáta, Szabó, Ella, Kardos, Viktor, Bálint, Anita, Farkas, Klaudia, Milassin, Ágnes, Rutka, Mariann, Szántó, Kata, Molnár, Tamás, Szűcs, Mónika, Lőrinczy, Katalin, Orbán‐Szilágyi, Ákos, Gyökeres, Tibor, Gyimesi, György, Szepes, Attila, Kovács, Valéria, Rácz, István, and Szepes, Zoltán

Subjects
ARGON plasmas, ERYTHROCYTES, ELECTROCOAGULATION (Medicine), BLOOD transfusion
Abstract

Objective: The efficacy of argon plasma coagulation (APC) on gastric antral vascular ectasia (GAVE) may be impaired over time and depends greatly on the application settings. Endoscopic band ligation (EBL) may be an alternative, but study on its efficacy is limited. This study aimed to evaluate and compare the clinical efficacy of APC and EBL in treating GAVE. Methods: Changes in the need for blood transfusion, number of treatment sessions and hospitalizations were retrospectively assessed in 63 transfusion‐dependent patients with GAVE (mean age: 67.1 y, 54.0% female) treated with either APC or EBL (45 and 18 patients, respectively) in four tertiary endoscopic centers. Results: Both methods substantially increased hemoglobin levels and decreased patients' need for a transfusion (22.0 ± 4.0 g/L and −5.62 ± 2.30 units of packed red blood cells [RBC] with APC, and 27.4 ± 6.1 g/L and −4.79 ± 2.46 units of packed RBC with EBL), without a significant statistical difference between the methods. However, fewer EBL sessions were required both for the cessation of need for a transfusion compared with those for the resolution of GAVE lesions (0.90 ± 0.10 vs 1.69 ± 0.31, P = 0.028). Conclusions: Both APC and EBL are effective in GAVE treatment. EBL may be superior in terms of number of treatment sessions, but not in its influence on hemoglobin level and need for transfusion. Further prospective studies with large, homogeneous sample size and standardized APC settings are needed. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

115. Additional file 1: of Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases

Author

Lorant Gonczi, Kurti, Zsuzsanna, Rutka, Mariann, Vegh, Zsuzsanna, Farkas, Klaudia, Lovasz, Barbara, Golovics, Petra, Gecse, Krisztina, Balazs Szalay, Molnar, Tamas, and Lakatos, Peter

Abstract

Data set. We provided the dataset of our research as requested by the guidelines of BMC Gastroenterology. All available result of our dataset is presented in the manuscript. (DOCX 90Â kb)

Published
2017
Full Text
View/download PDF

116. Gyulladásos bélbetegségben szenvedő gyermekek kezelésének átadása felnőttszakrendelésre. 10 éves tapasztalataink összegzése

Author

Szántó, Kata, primary, Szűcs, Dániel, additional, Vass, Noémi, additional, Várkonyi, Ágnes, additional, Bálint, Anita, additional, Bor, Renáta, additional, Fábián, Anna, additional, Milassin, Ágnes, additional, Rutka, Mariann, additional, Szepes, Zoltán, additional, Nagy, Ferenc, additional, Molnár, Tamás, additional, and Farkas, Klaudia, additional

Published
2018
Full Text
View/download PDF

117. Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis – results from multicenter observational cohort

Author

Bálint, Anita, primary, Rutka, Mariann, additional, Kolar, Martin, additional, Bortlik, Martin, additional, Duricova, Dana, additional, Hruba, Veronika, additional, Lukas, Martin, additional, Mitrova, Katarina, additional, Malickova, Karin, additional, Lukas, Milan, additional, Szepes, Zoltán, additional, Nagy, Ferenc, additional, Palatka, Károly, additional, Lovas, Szilvia, additional, Végh, Zsuzsanna, additional, Kürti, Zsuzsanna, additional, Csontos, Ágnes, additional, Miheller, Pál, additional, Nyári, Tibor, additional, Bor, Renáta, additional, Milassin, Ágnes, additional, Fábián, Anna, additional, Szántó, Kata, additional, Lakatos, Péter L, additional, Molnár, Tamás, additional, and Farkas, Klaudia, additional

Published
2018
Full Text
View/download PDF

118. Biological therapy and surgery rates in inflammatory bowel diseases – Data analysis of almost 1000 patients from a Hungarian tertiary IBD center

Author

Szántó, Kata, primary, Nyári, Tibor, additional, Bálint, Anita, additional, Bor, Renáta, additional, Milassin, Ágnes, additional, Rutka, Mariann, additional, Fábián, Anna, additional, Szepes, Zoltán, additional, Nagy, Ferenc, additional, Molnár, Tamás, additional, and Farkas, Klaudia, additional

Published
2018
Full Text
View/download PDF

121. Mo1843 - Non-Medical Mandatory Reversed and Back and Forth Switch Between Infliximab and its Biosimilar: Early Clinical Outcomes

Author

Ilias, Akos, primary, Szanto, Kata, additional, Gonczi, Lorant, additional, Kurti, Zsuzsanna, additional, Golovics, Petra Anna, additional, Szamosi, Tamas, additional, Schafer, Eszter, additional, Farkas, Klaudia, additional, Szepes, Zoltán, additional, Molnar, Tamas, additional, Vincze, Aron, additional, and Lakatos, Peter L., additional

Published
2018
Full Text
View/download PDF

123. How disease extent can be included in the endoscopic activity index of ulcerative colitis: the panMayo score, a promising scoring system

Author

Bálint, Anita, primary, Farkas, Klaudia, additional, Szepes, Zoltán, additional, Nagy, Ferenc, additional, Szűcs, Mónika, additional, Tiszlavicz, László, additional, Bor, Renáta, additional, Milassin, Ágnes, additional, Rutka, Mariann, additional, Fábián, Anna, additional, and Molnár, Tamás, additional

Published
2018
Full Text
View/download PDF

124. The Use of Complementary and Alternative Medicine Is Less Frequent in Patients with Inflammatory Bowel Disease Than in Patients with Other Chronic Gastrointestinal Disorders

Author

Fábián, Anna, primary, Rutka, Mariann, additional, Ferenci, Tamás, additional, Bor, Renáta, additional, Bálint, Anita, additional, Farkas, Klaudia, additional, Milassin, Ágnes, additional, Szántó, Kata, additional, Lénárt, Zsuzsanna, additional, Nagy, Ferenc, additional, Szepes, Zoltán, additional, and Molnár, Tamás, additional

Published
2018
Full Text
View/download PDF

126. Henoch-Schönlein purpura presenting with multiplex gastrointestinal manifestations and massive nephrotic syndrome in adulthood — a case report

Author

Kemény Éva, Wittmann Tibor, Tiszlavicz László, Németh István, Molnár Tamás, Varga Erika, Nagy Ferenc, and Farkas Klaudia

Subjects
Pathology, medicine.medical_specialty, Kidney, Henoch-Schonlein purpura, Proteinuria, medicine.diagnostic_test, business.industry, digestive, oral, and skin physiology, Ileum, General Medicine, medicine.disease, digestive system, Purpura, medicine.anatomical_structure, Biopsy, medicine, medicine.symptom, business, Antrum, Nephrotic syndrome
Abstract

Henoch-Schönlein purpura (HSP) is a systemic small vessel vasculitis mainly affecting children. We report a case of a 49-year-old woman with severe gastrointestinal and renal involvement of HSP. Endoscopy revealed more characteristic findings in the terminal ileum than in the gastric antrum. Histological examinations of the biopsy samples from the ileum, antrum, skin and kidney confirmed the diagnosis of HSP. Parenteral corticosteroid therapy led to a rapid improvement of the gastrointestinal symptoms, but because of the excessive proteinuria intravenous cyclophosphamide therapy had to be introduced.

Published
2008
Full Text
View/download PDF

130. Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn’s disease and ulcerative colitis – experiences from a single center

Author

Farkas, Klaudia, primary, Rutka, Mariann, additional, Ferenci, Tamás, additional, Nagy, Ferenc, additional, Bálint, Anita, additional, Bor, Renáta, additional, Milassin, Ágnes, additional, Fábián, Anna, additional, Szántó, Kata, additional, Végh, Zsuzsanna, additional, Kürti, Zsuzsanna, additional, Lakatos, Péter L., additional, Szepes, Zoltán, additional, and Molnár, Tamás, additional

Published
2017
Full Text
View/download PDF

131. Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases

Author

Gonczi, Lorant, primary, Kurti, Zsuzsanna, additional, Rutka, Mariann, additional, Vegh, Zsuzsanna, additional, Farkas, Klaudia, additional, Lovasz, Barbara D., additional, Golovics, Petra A., additional, Gecse, Krisztina B., additional, Szalay, Balazs, additional, Molnar, Tamas, additional, and Lakatos, Peter L., additional

Published
2017
Full Text
View/download PDF

133. Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort

Author

Bálint, Anita, primary, Rutka, Mariann, additional, Végh, Zsuzsanna, additional, Kürti, Zsuzsanna, additional, Gecse, Krisztina B., additional, Banai, János, additional, Bene, László, additional, Gasztonyi, Beáta, additional, Kristóf, Tünde, additional, Lakatos, László, additional, Miheller, Pál, additional, Palatka, Károly, additional, Patai, Árpád, additional, Salamon, Ágnes, additional, Szamosi, Tamás, additional, Szepes, Zoltán, additional, Tóth, Gábor Tamás, additional, Vincze, Áron, additional, Bor, Renáta, additional, Milassin, Ágnes, additional, Fábián, Anna, additional, Nagy, Ferenc, additional, Kolar, Martin, additional, Bortlik, Martin, additional, Duricova, Dana, additional, Hruba, Veronika, additional, Lukas, Martin, additional, Mitrova, Katarina, additional, Malickova, Karin, additional, Lukas, Milan, additional, Lakatos, Péter L., additional, Molnár, Tamás, additional, and Farkas, Klaudia, additional

Published
2017
Full Text
View/download PDF

134. Pregnancy does not affect fecal calprotectin concentration in healthy women

Author

Bálint, Anita, primary, Berényi, Anna, additional, Farkas, Klaudia, additional, Pallagi Kunstár, Éva, additional, Altorjay, Ábel, additional, Csonka, Andrea, additional, Krizsán, Mária, additional, Szucs, Mónika, additional, Pál, Attila, additional, Fábián, Anna, additional, Bor, Renáta, additional, Milassin, Ágnes, additional, Szulcsán, Ádám, additional, Mariann, Rutka, additional, Szepes, Zoltán, additional, and Molnár, Tamás, additional

Published
2017
Full Text
View/download PDF

135. Final Results on Immunogenicity Profile and Predictors of ADA Development of Biosimilar Infliximab During the First 12 Months of the Therapy: Results from a Prospective Nationwide Cohort

Author

Kurti, Zsuzsanna, primary, Lovasz, Barbara Dorottya, additional, Rutka, Mariann, additional, Vegh, Zsuzsanna, additional, Gecse, Krisztina, additional, Farkas, Klaudia, additional, Banai, Jã¡nos, additional, Bene, Laszlo, additional, Golovics, Petra Anna, additional, Gonczi, Lorant, additional, Gasztonyi, Beata, additional, Kristof, Tunde, additional, Lakatos, Laszlo, additional, Miheller, Pal, additional, Palatka, Karoly, additional, Patai, Arpad, additional, Papp, Maria, additional, Salamon, Agnes, additional, Szamosi, Tamas, additional, Szepes, Zoltán, additional, Toth, Gabor Tamas, additional, Vincze, Aron, additional, Szalay, Balazs, additional, Molnar, Tamas, additional, and Lakatos, Peter L., additional

Published
2017
Full Text
View/download PDF

136. Final Results on Efficacy and Safety of Biosimilar Infliximab after One-Year: Results from a Prospective Nationwide Cohort

Author

Gecse, Krisztina, primary, Vegh, Zsuzsanna, additional, Kurti, Zsuzsanna, additional, Rutka, Mariann, additional, Farkas, Klaudia, additional, Golovics, Petra Anna, additional, Lovasz, Barbara Dorottya, additional, Gonczi, Lorant, additional, Banai, János, additional, Bene, Laszlo, additional, Gasztonyi, Beata, additional, Kristof, Tunde, additional, Lakatos, Laszlo, additional, Miheller, Pal, additional, Nagy, Ferenc, additional, Palatka, Karoly, additional, Papp, Maria, additional, Patai, Arpad, additional, Salamon, Agnes, additional, Szamosi, Tamas, additional, Szepes, Zoltán, additional, Toth, Gabor Tamas, additional, Vincze, Aron, additional, Molnar, Tamas, additional, and Lakatos, Peter L., additional

Published
2017
Full Text
View/download PDF

138. Analysis of risk factors - especially different types of plexitis - for postoperative relapse in Crohn’s disease

Author

Milassin, Ágnes, primary, Sejben, Anita, additional, Tiszlavicz, László, additional, Reisz, Zita, additional, Lázár, György, additional, Szűcs, Mónika, additional, Bor, Renáta, additional, Bálint, Anita, additional, Rutka, Mariann, additional, Szepes, Zoltán, additional, Nagy, Ferenc, additional, Farkas, Klaudia, additional, and Molnár, Tamás, additional

Published
2017
Full Text
View/download PDF

139. What Is the Personal Experience of IBD Patients about Their Anti-TNF-Alpha Therapy?

Author

Milassin, Ágnes, primary, Rutka, Mariann, additional, Csontos, Ágnes Anna, additional, Miheller, Pál, additional, Palatka, Károly, additional, Szűcs, Mónika, additional, Szepes, Zoltán, additional, Bálint, Anita, additional, Bor, Renáta, additional, Fábián, Anna, additional, Farkas, Klaudia, additional, Nagy, Ferenc, additional, and Molnár, Tamás, additional

Published
2017
Full Text
View/download PDF

141. Real-life efficacy of vedolizumab on endoscopic healing in inflammatory bowel disease – A nationwide Hungarian cohort study

Author

Bor, Renáta, Fábián, Anna, Matuz, Mária, Szepes, Zoltán, Farkas, Klaudia, Miheller, Pál, Szamosi, Tamás, Vincze, Áron, Rutka, Mariann, Szántó, Kata, Bálint, Anita, Nagy, Ferenc, Milassin, Ágnes, Tóth, Tibor, Zsigmond, Ferenc, Bajor, Judit, Müllner, Katalin, Lakner, Lilla, Papp, Mária, Salamon, Ágnes, Horváth, Gábor, Sarang, Krisztina, Schäfer, Eszter, Sarlós, Patrícia, Palatka, Károly, and Molnár, Tamás

Abstract

ABSTRACTBackground: GEMINI trials demonstrated the therapeutic efficacy of vedolizumab (VDZ) in Crohn’s disease (CD) and ulcerative colitis (UC).Research design and methods: Aim of this study was to determine the real-life effectiveness of VDZ on endoscopic healing in the Hungarian nationwide cohort of inflammatory bowel disease (IBD) patients based on the changes on clinical and endoscopic scores. Every adult IBD patient in the country (121 UC and 83 CD) who completed the short-term VDZ therapy was enrolled, of which 72 UC and 52 CD patients could complete the long-term therapy.Results: The rates of endoscopic healing were substantially higher in UC compared with CD patients during the short- and long-term therapy (52.9% vs. 21.7%, p< 0.0001, and 51.4% vs. 21.2%, p= 0.015, respectively). In CD, the rate of endoscopic healing was lower at week 14 compared with week 22 (14.5% vs. 37.0%, p= 0.026). Prior anti-TNF-α therapy (88.73%) was not associated with a significant decrease in therapeutic response. The average disease duration was significantly lower in CD patients achieving endoscopic healing at week 52 (11.75 vs. 5.27 years, p= 0.007).Conclusions: VDZ therapy is an effective therapeutic option in anti-TNF-α refractory IBD. However, the endoscopic healing rate was substantially lower and showed a significant delay in CD compared with UC.

Published
2020
Full Text
View/download PDF

143. Prediction of Short- and Medium-term Efficacy of Biosimilar Infliximab Therapy. Do Trough Levels and Antidrug Antibody Levels or Clinical And Biochemical Markers Play the More Important Role?

Author

Gonczi, Lorant, primary, Vegh, Zsuzsanna, additional, Golovics, Petra Anna, additional, Rutka, Mariann, additional, Gecse, Krisztina Barbara, additional, Bor, Renata, additional, Farkas, Klaudia, additional, Szamosi, Tamás, additional, Bene, László, additional, Gasztonyi, Beáta, additional, Kristóf, Tünde, additional, Lakatos, László, additional, Miheller, Pál, additional, Palatka, Károly, additional, Papp, Mária, additional, Patai, Árpád, additional, Salamon, Ágnes, additional, Tóth, Gábor Tamás, additional, Vincze, Áron, additional, Biro, Edina, additional, Lovasz, Barbara Dorottya, additional, Kurti, Zsuzsanna, additional, Szepes, Zoltan, additional, Molnár, Tamás, additional, and Lakatos, Péter L., additional

Published
2016
Full Text
View/download PDF

144. Prognostic factors, effectiveness and safety of endoscopic balloon dilatation for de novo and anastomotic strictures in Crohn’s disease—A multicenter “real life” study

Author

Bálint, Anita, primary, Törőcsik, Dalma, additional, Palatka, Károly, additional, Szepes, Zoltán, additional, Szűcs, Mónika, additional, Tamás, Ferenci, additional, Nagy, Ferenc, additional, Farkas, Klaudia, additional, Fábián, Anna, additional, Bor, Renáta, additional, Milassin, Ágnes, additional, Rutka, Mariann, additional, and Molnár, Tamás, additional

Published
2016
Full Text
View/download PDF

145. Prospective Comparison of Magnetic Resonance Imaging, Transrectal and Transperineal Sonography, and Surgical Findings in Complicated Perianal Crohn Disease

Author

Bor, Renáta, primary, Farkas, Klaudia, additional, Bálint, Anita, additional, Szűcs, Mónika, additional, Ábrahám, Szabolcs, additional, Milassin, Ágnes, additional, Rutka, Mariann, additional, Nagy, Ferenc, additional, Milassin, Péter, additional, Szepes, Zoltán, additional, and Molnár, Tamás, additional

Published
2016
Full Text
View/download PDF

147. Gastroduodenal Involvement in Asymptomatic Crohn’s Disease Patients in Two Areas of Emerging Disease: Asia and Eastern Europe

Author

Farkas, Klaudia, primary, Chan, Heyson, additional, Rutka, Mariann, additional, Szepes, Zoltán, additional, Nagy, Ferenc, additional, Tiszlavicz, László, additional, Nyári, Tibor, additional, Tang, Whitney, additional, Wong, Grace, additional, Tang, Raymond, additional, Lo, Angeline, additional, Cheung, Christina, additional, Wong, Sunny, additional, Lui, Rashid, additional, Molnár, Tamás, additional, and Ng, Siew C, additional

Published
2016
Full Text
View/download PDF

148. Az adalimumab hatékonysága és biztonságossága hagyományos kezelésre refrakter colitis ulcerosában

Author

Rutka, Mariann, primary, Bálint, Anita, additional, Farkas, Klaudia, additional, Palatka, Károly, additional, Lakner, Lilla, additional, Miheller, Pál, additional, Rácz, István, additional, Hegede, Gábor, additional, Vincze, Áron, additional, Horváth, Gábor, additional, Szabó, Andrea, additional, Nagy, Ferenc, additional, Szepes, Zoltán, additional, Gábor, Zoltán, additional, Zsigmond, Ferenc, additional, Zsóri, Ágnes, additional, Juhász, Márk, additional, Csontos, Ágnes, additional, Szűcs, Mónika, additional, Bor, Renáta, additional, Milassin, Ágnes, additional, and Molnár, Tamás, additional

Published
2016
Full Text
View/download PDF

149. Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis

Author

Farkas, Klaudia, primary, Rutka, Mariann, additional, Golovics, Petra A., additional, Végh, Zsuzsanna, additional, Lovász, Barbara D., additional, Nyári, Tibor, additional, Gecse, Krisztina B., additional, Kolar, Martin, additional, Bortlik, Martin, additional, Duricova, Dana, additional, Machkova, Nadezda, additional, Hruba, Veronika, additional, Lukas, Martin, additional, Mitrova, Katarina, additional, Malickova, Karin, additional, Bálint, Anita, additional, Nagy, Ferenc, additional, Bor, Renáta, additional, Milassin, Ágnes, additional, Szepes, Zoltán, additional, Palatka, Károly, additional, Lakatos, Péter L., additional, Lukas, Milan, additional, and Molnár, Tamás, additional

Published
2016
Full Text
View/download PDF

150. Sa1936 Efficacy and Safety of Biosimilar Infliximab After One-Year: Results From a Prospective Nationwide Cohort

Author

Gecse, Krisztina, primary, Vegh, Zsuzsanna, additional, Kurti, Zsuzsanna, additional, Rutka, Mariann, additional, Farkas, Klaudia, additional, Golovics, Petra A., additional, Lakatos, Laszlo, additional, Miheller, Pal, additional, Palatka, Karoly, additional, Patai, Árpád V., additional, Szamosi, Tamas, additional, Szepes, Zoltan, additional, Vincze, Aron, additional, Molnar, Tamas, additional, and Lakatos, Peter L., additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results